This annual recap highlights Goodwin’s continued determination and agility as a full-service, integrated global practice. Committed to being a global destination life cycle law firm to the life sciences industry, we are proud to stand alongside and counsel leading life sciences companies driving transformative innovation. Our ongoing client partnerships inspire us; we look forward to navigating the evolving life sciences landscape together in 2024 and beyond.
By The Numbers
(Representation of both issuers and underwriters)
Global Market Recognition
Notable Deals
Counsel to Globus Medical on its $3.1 billion definitive agreement to combine with NuVasive in an all-stock transaction.
Counsel to Royalty Pharma in its agreement with PTC Therapeutics to acquire additional royalties on Roche’s Evrysdi for up to $1.5 billion.
Counsel to Versanis Bio in its $1.925 billion definitive agreement to be acquired by Eli Lilly and Company.
Counsel to ElevateBio in its $401 million Series D financing.
Counsel to Teva Pharmaceuticals on its $1 billion collaboration with Sanofi.
Counsel to Seagen on its $3.4 billion multi-target strategic collaboration agreement with Nurix Therapeutics.
Counsel to Mablink Bioscience in its agreement to be acquired by Eli Lilly and Company.
Regulatory Initiatives
Rare Disease Initiative
Our rare disease initiative works with biotech, pharmaceutical, medical technology, and diagnostic companies and their investors, partners, and key stakeholders focused on developing solutions for countless rare medical conditions.
Inflation Reduction Act
Our resource covers updates and analysis about the Inflation Reduction Act and the ways it could change how government pays for pharmaceuticals and biologics.
Laboratory Developed Tests
We provide foundational materials, legislative and regulatory history, and updates and analyses regarding initiatives to increase oversight over laboratory developed tests (LDTs).
A Look Ahead in Life Sciences
Read our overview of key developments in the legal, regulatory, and compliance landscape for the life sciences, medtech, and diagnostic industries.
